# 3Z

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/3z

- Industry: Biotechnology
- Headquarters: Reykjavík, Iceland
- Website: www.3z.is
- Total disclosed funding: $0.6M
- Latest round: Seed (Oct 12, 2020)
- Investors on record: 3

## About

Based in Reykjavik, Iceland, and founded in 2008 by CEO Karl Karlsson, and CSO Haraldur Thorsteinsson, 3Z Ltd., a.k.a. 3Z Pharmaceuticals develops repurposed small molecule drugs that target neurological indications based on its zebrafish screening technology. In June 2022, 3Z Ltd. closed USD 2 million funding round led by seasoned investors in pharmaceuticals and medical technology.

The company product pipeline includes novel ADHD therapeutics, such as 3Z-20-001, 3Z-20-002, 3Z-20-003, and 3Z-20-004 used to treat neurological disorders, enabling patients to get multiple drug efficacy and toxicity assays. 3Z Pharmaceuticals has utilized its zebrafish screening platform to identify novel and repurposed therapeutics candidates for insomnia and ADHD. Insomnia therapeutics encompasses a novel mechanism of action that may combat insomnia and metabolic syndrome, indications with significant comorbidity. The novel ADHD therapeutics are all non-stimulants, poised to fill a gap in the market, with fewer side effects compared to contemporary treatments, and offer an alternative for non-responders.

3Z Pharmaceuticals plans to use its proceeds from June 2022 funding to accelerate the preclinical development of lead therapeutic candidates in ADHD and insomnia.

## Funding rounds

- Seed, Oct 12, 2020, $0.2M — New Business Venture Fund, Probiocon GmbH
- Seed, Jul 5, 2016, $0.4M — PROMETHERA Biosciences S.A./N.V., New Business Venture Fund, Probiocon GmbH
- Seed, May 16, 2012 — New Business Venture Fund

## Investors

- New Business Venture Fund (https://capitalatlas.ai/funds/new-business-venture-fund) — Seed
- PROMETHERA Biosciences S.A./N.V. — Seed
- Probiocon GmbH — Seed